11 Dec 2017
N+1 Singer - Abzena - US contract win highlights successful services integration
The Master Services Agreement with a US biotech, worth in excess of $5m, highlights the integrated nature of Abzena’s offering across chemistry services, cell line development and GMP manufacturing. We continue to expect strong growth in non-licensing revenue (30% CAGR FY2017-20), propelled in particular by rapid expected growth in manufacturing-related income following the installation of stirred-tank bioreactors (due to become operational in early 2018). Interim results are due tomorrow 12th D ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Abzena - US contract win highlights successful services integration
Abzena (ABZA:LON) | 0 0 (-0.9%) | Mkt Cap: 54.0m
- Published:
11 Dec 2017 -
Author:
Dr Jens Lindqvist -
Pages:
3
The Master Services Agreement with a US biotech, worth in excess of $5m, highlights the integrated nature of Abzena’s offering across chemistry services, cell line development and GMP manufacturing. We continue to expect strong growth in non-licensing revenue (30% CAGR FY2017-20), propelled in particular by rapid expected growth in manufacturing-related income following the installation of stirred-tank bioreactors (due to become operational in early 2018). Interim results are due tomorrow 12th D ....